Illumina, Inc. (ILMN)

Illumina's stock price has increased by 60.31% in the past six months. In Q2 2025, Illumina beat revenue expectations but missed adjusted EPS estimates, raising its full-year adjusted EPS guidance. The launch of BioInsight was announced in October 2025. In Q3 2025, the company reported EPS and revenue slightly above estimates. A collaboration with MyOme in December 2025 coincided with a stock move. A J.P. Morgan Conference Webcast Notice in December 2025 saw a modest decline in stock price. The release of Illumina Connected Multiomics in January 2026 led to a jump in ILMN shares. Leadership changes in January 2026 resulted in a stock movement. Preliminary unaudited financial results for Q4 and FY 2025 were announced in January 2026, updating FY 2025 earnings guidance above Wall Street's consensus.

While there isn't a strong, consistent seasonal pattern explicitly detailed, the demand for sequencing consumables is often recurring. The company's revenue is driven by the growing interest in genomic information and its application to research, clinical, and consumer markets. The focus on clinical market strength helps cushion weakness in the research segment. The introduction of new products and solutions also drives demand for associated consumables.

Illumina, Inc. is a biotechnology company focused on genetic and genomic analysis, headquartered in San Diego, California. Illumina develops, manufactures, and markets integrated systems for analyzing genetic variation and biological function, with a mission to improve human health by making genetic variation and function accessible and understandable. Its major products and services include DNA Sequencing Systems, Consumables, Genotyping and Gene Expression Products, Proteomics Markets, Software and Services, and the GRAIL Segment, including Galleri, a multi-cancer early detection test. Illumina's technologies are used by various entities worldwide, including genomic research centers, pharmaceutical companies, and hospitals.

Illumina has a global presence, serving more than 155 countries, and directly markets its products in North America, Europe, Latin America, and the Asia-Pacific region. It also collaborates with life-science distributors across Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Key revenue distribution by region includes Americas (55.8% of total revenue), EMEA (27.1%), Asia Pacific (10.0%), and China (7.0%). The company has offices and manufacturing/R&D facilities in locations such as San Diego, California, Madison, Wisconsin, Singapore, Israel, China, and Korea.

Illumina maintains a strong brand reputation as a global leader in DNA sequencing and array-based technologies. Product launches and innovations, such as BioInsight and Illumina Connected Multiomics, enhance its reputation as an innovator. Financial performance and strategic partnerships and acquisitions also influence its perception. Regulatory risks related to its GRAIL acquisition could impact reputation.

Illumina's ownership is heavily concentrated among institutional investors, who control roughly 85.00% of the company's stock. Major institutional owners include Capital World Investors, BlackRock, Inc., The Vanguard Group, Inc., and State Street Corp. Keith A. Meister is the largest individual Illumina shareholder, owning 5.02% of the company. Insiders hold approximately 2.79% of the stock.